News

Pharma sector, FMI report says, is quickly growing, due to globalization and development of low-cost medications.

Facility addition expected to increase production capacity of TNAs.

Investment helps encourage sustainability in the space, especially as it pertains to pharma, company says.

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.

Conclusion driven by various factors, including product shortages and cost pressures.

Flights from Colombia and Ecuador more than doubled during the season, resulting in exports of nearly 18,000 tons.

South Korea facility expected to provide fill-finish capabilities.

New California plant expected to streamline medicine production.

Investment expected to establish additional cGMPs, expand CDMO services.

Joint venture expected to address pharma’s injectable drug-filling sector.

Purchase doubles staffing, adds global capabilities.

Collaboration to support biotech company’s clinical and commercial production efforts.

Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.

Global air freight market data suggests only a 1.6% demand drop off compared to 2019.

Saint-Beauzire complex dedicated to sterile liquid drug production.

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.

Location serves as the US flagship for company’s global pharma development network.

In effort to preserve medication, contribution will provide 150 refrigeration units across 17 countries.

The latest people news happenings over the past month.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.

Complex to develop cGMP-compliant, commercial-scale plasmid DNA.

Companies to release variety of options for this sector.

Platform expected to allow customers to meet various logistics requirements, company says.

Expansion expected to help tackle health issues at a faster rate, company says

Annual report finds continuing impact of COVID-19 on global markets